Geron Corporation granted stock options for 570,000 shares to three new employees as inducement to join the company, effective October 16, 2026. The options have an exercise price of $1.17 per share, matching the stock's closing price on the grant date, with a 10-year term and vesting over four years. This move is part of Geron's strategy to attract talent in its hematology-focused biopharmaceutical business, which includes developing treatments for blood cancer. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are governed by Geron's 2018 Inducement Award Plan.
Geron Corporation's recent inducement grants come as part of a dynamic health sector market. For readers following health stocks, here is Pluang's market snapshot as of Oct 20, 2026 01:32 WIB: out of 150 priced US health-sector stocks tradable on Pluang, 84 rose and 62 fell today. Notable movers include NVAX (Novavax Inc) at USD 10.81 with a 36% Sell / 64% Buy order activity and a typical hold time of 59 days, RXRX (Recursion Pharmaceuticals Inc) at USD 3.60 with a 72% Sell / 28% Buy order activity and a typical hold time of 21 days, and TNGX (Tango Therapeutics Inc.) at USD 22.86 with a typical hold time of 5 days.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
